Single Dose, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Subcutaneous Injection of PolyPEPI1018 Vaccine as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer (CRC)
Phase of Trial: Phase I
Latest Information Update: 12 Jul 2018
At a glance
- Drugs PolyPEPI 1018 (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; First in man
- Acronyms OBERTO
- Sponsors Treos Bio
- 14 May 2018 According to a Treos Bio media release, first patient has been dosed.
- 11 Apr 2018 According to a Treos Bio media release, Mayo Clinic, the only U.S. site has been activated.
- 11 Apr 2018 Status changed from not yet recruiting to recruiting, according to a Treos Bio media release.